KYNTRA BIO, INC. Income (Loss) from Continuing Operations, Per Diluted Share
KYNTRA BIO, INC. (KYNB) reported Income (Loss) from Continuing Operations, Per Diluted Share of $2.96 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare · last filed 2026-08-13
- KYNTRA BIO, INC. income (loss) from continuing operations, per diluted share for the quarter ending 2026-06-30 was $2.96.
- KYNTRA BIO, INC. income (loss) from continuing operations, per diluted share for the quarter ending 2026-03-31 was -$3.74.
- KYNTRA BIO, INC. income (loss) from continuing operations, per diluted share for the quarter ending 2025-09-30 was -$3.25.
- KYNTRA BIO, INC. income (loss) from continuing operations, per diluted share for the quarter ending 2025-06-30 was -$3.38.
- KYNTRA BIO, INC. income (loss) from continuing operations, per diluted share for fiscal 2025 was -$14.40.
- KYNTRA BIO, INC. income (loss) from continuing operations, per diluted share for fiscal 2024 was -$38.26.
- KYNTRA BIO, INC. income (loss) from continuing operations, per diluted share for fiscal 2023 was -$3.32.
| Period end | Income (Loss) from Continuing Operations, Per Diluted Share 3 month | Income (Loss) from Continuing Operations, Per Diluted Share 3 month as first filed | Income (Loss) from Continuing Operations, Per Diluted Share 6 month | Income (Loss) from Continuing Operations, Per Diluted Share 9 month | Income (Loss) from Continuing Operations, Per Diluted Share 12 month | Income (Loss) from Continuing Operations, Per Diluted Share 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2.96 10-Q · filed 2026-08-13 | -$0.78 10-Q · filed 2026-08-13 | ||||
| 2026-03-31 | -$3.74 10-Q · filed 2026-05-12 | |||||
| 2025-12-31 | -$14.40 10-K · filed 2026-03-16 | |||||
| 2025-09-30 | -$3.25 10-Q · filed 2025-11-10 | -$10.79 10-Q · filed 2025-11-10 | ||||
| 2025-06-30 | -$3.38 10-Q · filed 2026-08-13 | -$7.54 10-Q · filed 2026-08-13 | ||||
| 2025-03-31 | -$4.15 10-Q · filed 2026-05-12 | -$0.16 10-Q · filed 2025-05-12 | ||||
| 2024-12-31 | -$38.26 10-K · filed 2026-03-16 | -$1.53 10-K · filed 2025-03-17 | ||||
| 2024-09-30 | -$12.01 10-Q · filed 2025-11-10 | -$36.19 10-Q · filed 2025-11-10 | ||||
| 2024-06-30 | -$11.79 10-Q · filed 2025-08-11 | -$24.18 10-Q · filed 2025-08-11 | ||||
| 2024-03-31 | -$0.49 10-Q · filed 2025-05-12 | |||||
| 2023-12-31 | -$3.32 10-K · filed 2025-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 |